Cellserve GmbH
Product Strategy
Product strategy
1st and 2nd Generation Product
After the 1st generation “CardAPcells”, a 2nd generation allogeneic “off-the shelf” product “AlloCardAP” brings immense upside potential and enables manufacturing of large quantities, thus improving scalability
1st Product Generation
CardAPcells
Cardiac-derived Adherent Proliferating Cells (CardAPcells)
Initial focus on the production of a autologous cell product: The cells are obtained from heart muscle biopsies of the patient himself, cultivated externally, worked up and transplanted into the same patient.
2nd Product Generation
AlloCardAP
The development of an allogeneic „off the shelf“ cell therapy product is in process
- CardAPCELLS have already proven low immunogenicity and are hence very promising to be successfully applied as an allogeneic product
- Large cell batches can be used for many patients from a single tissue donation
- Simple and cost-effective logistics
- Cost reduction ensures the support of health insurances and hospitals
Allogeneic cell preparation can be produced in large amounts, comparable to a conventional drug, „off the shelf“ is more appealing to traditional pharmaceutical companies
CardAPcells
Cardiac-derived Adherent Proliferating (CardAPcells):
Proprietary novel cells derived from heart tissue for therapy of chronic myocardial heart insufficiency
How it works
CardAPcells are cultivated using the patients‘ own cells:
Cells derived from heart tissue for the novel proprietary therapy of chronic myocardial heart insufficiency
About us
Our innovative cell therapy development focuses specifically on strengthening the heart muscle and the natural healing processes in the heart